Mustang Bio Announces Participation in Upcoming Scientific Meetings
Management team to speak at 2nd In Vivo Engineering of Therapeutic Cells Summit and 8th…
News
Mustang Bio Announces Participation in Upcoming Scientific Meetings
Management team to speak at 2nd In Vivo Engineering of Therapeutic Cells Summit and 8th…
T2 Biosystems Announces Conversion of Approximately Twenty Percent of CRG Term Loan into Equity
LEXINGTON, Mass., July 06, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the…
T2 Biosystems Announces Conversion of Approximately Twenty Percent of CRG Term Loan into Equity
LEXINGTON, Mass., July 06, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the…
NKGen Biotech Inc. and Graf Acquisition Corp. IV to Co-Host Investor Event
SANTA ANA, Calif. and THE WOODLANDS, Texas, July 06, 2023 (GLOBE NEWSWIRE) — NKGen Biotech…
NKGen Biotech Inc. and Graf Acquisition Corp. IV to Co-Host Investor Event
SANTA ANA, Calif. and THE WOODLANDS, Texas, July 06, 2023 (GLOBE NEWSWIRE) — NKGen Biotech…
gammaCore™ Non-Invasive Vagal Nerve Stimulation Selected for Study Funded by the National Football League (NFL) and National Football League Players Association (NFLPA) on Alleviating Concussion Symptoms
ROCKAWAY, N.J., July 06, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine…
gammaCore™ Non-Invasive Vagal Nerve Stimulation Selected for Study Funded by the National Football League (NFL) and National Football League Players Association (NFLPA) on Alleviating Concussion Symptoms
ROCKAWAY, N.J., July 06, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine…
PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC
· Agreement for PAX-101 (suramin IV) Distribution in the U.S. for up to 7 years…
PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC
· Agreement for PAX-101 (suramin IV) Distribution in the U.S. for up to 7 years…
Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation
NEW YORK and LONDON, July 06, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX),…
Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation
NEW YORK and LONDON, July 06, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX),…
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at Global Food Allergy Prevention Summit
WARREN, N.J., July 06, 2023 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company”…
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at Global Food Allergy Prevention Summit
WARREN, N.J., July 06, 2023 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company”…
Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate
Met all primary endpoints: Vaccine was well-tolerated with robust immunogenicity Continue to expect topline data…
ViaDerma Announces Updates for Vitastem Global Sales Expansion, Nupelo FDA-Registration Status & More
LOS ANGELES, July 06, 2023 (GLOBE NEWSWIRE) — ViaDerma, Inc. (OTC Pink: VDRM) is very…
Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate
Met all primary endpoints: Vaccine was well-tolerated with robust immunogenicity Continue to expect topline data…
ViaDerma Announces Updates for Vitastem Global Sales Expansion, Nupelo FDA-Registration Status & More
LOS ANGELES, July 06, 2023 (GLOBE NEWSWIRE) — ViaDerma, Inc. (OTC Pink: VDRM) is very…
Eblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2b Study in Atopic Dermatitis
Key study results Key efficacy endpoints Eblasakimab is the first biologic in moderate-to-severe atopic dermatitis…
Eblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2b Study in Atopic Dermatitis
Key study results Key efficacy endpoints Eblasakimab is the first biologic in moderate-to-severe atopic dermatitis…